Clinical Trial Update: Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of Bevacizumab and Erlotinib in patients with carcinoma of unknown primary; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Neoplasms, Unknown Primary | Phase 2 | Status: COMPLETED